Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
5.59
-0.83 (-12.93%)
At close: Sep 12, 2024, 4:00 PM
6.25
+0.66 (11.81%)
Pre-market: Sep 13, 2024, 8:00 AM EDT
Nkarta Employees
Nkarta had 150 employees as of December 31, 2023. The number of employees decreased by 13 or -7.98% compared to the previous year.
Employees
150
Change (1Y)
-13
Growth (1Y)
-7.98%
Revenue / Employee
n/a
Profits / Employee
-$719,400
Market Cap
394.42M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 150 | -13 | -7.98% |
| Dec 31, 2022 | 163 | 27 | 19.85% |
| Dec 31, 2021 | 136 | 41 | 43.16% |
| Dec 31, 2020 | 95 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sonida Senior Living | 3,955 |
| ZimVie | 2,600 |
| Varex Imaging | 2,400 |
| Sage Therapeutics | 487 |
| Quanterix | 441 |
| Prime Medicine | 234 |
| C4 Therapeutics | 145 |
| Aura Biosciences | 89 |
NKTX News
- 9 days ago - Nkarta to Participate in Upcoming Investor Conference - GlobeNewsWire
- 4 weeks ago - Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients - Seeking Alpha
- 4 weeks ago - Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 4 weeks ago - Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 7 weeks ago - Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus - GlobeNewsWire
- 2 months ago - Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President - GlobeNewsWire
- 2 months ago - Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications - GlobeNewsWire
- 3 months ago - Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors - GlobeNewsWire